Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17137458 | Cathepsin C inhibitors | December 2020 | September 2024 | Abandon | 45 | 1 | 0 | No | No |
| 17247757 | ACETYL-LEUCINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR IMPROVED MOBILITY AND COGNITIVE FUNCTION | December 2020 | April 2024 | Allow | 39 | 3 | 0 | No | No |
| 17254135 | New Substituted N9-Adenine Derivatives, Pharmaceutical Compositions Containing Same and Use Thereof | December 2020 | November 2023 | Allow | 35 | 2 | 0 | No | No |
| 17121874 | Polymeric Compositions for Intranasal Administration | December 2020 | December 2022 | Abandon | 24 | 3 | 1 | No | No |
| 16973836 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | December 2020 | December 2023 | Allow | 36 | 1 | 0 | No | No |
| 17115833 | METHODS OF TREATING CROHN'S DISEASE AND ULCERATIVE COLITIS | December 2020 | July 2024 | Abandon | 43 | 1 | 0 | No | No |
| 17110481 | METHODS OF TREATING COGNITIVE IMPAIRMENT ASSOCIATED WITH NEURODEGENERATIVE DISEASE | December 2020 | September 2023 | Abandon | 34 | 2 | 0 | No | No |
| 17108668 | PHENOXY THIOPHENE SULFONAMIDES AND OTHER COMPOUNDS FOR USE AS INHIBITORS OF BACTERIAL GLUCURONIDASE | December 2020 | May 2023 | Abandon | 29 | 0 | 1 | No | No |
| 17108266 | PHARMACEUTICAL COMPOUNDS | December 2020 | February 2023 | Allow | 26 | 2 | 0 | No | No |
| 17057700 | NICOTINE FORMULATION | November 2020 | August 2023 | Allow | 33 | 2 | 0 | No | No |
| 16953144 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | November 2020 | September 2022 | Allow | 22 | 1 | 0 | No | No |
| 17053737 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | November 2020 | May 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17089030 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | November 2020 | December 2022 | Abandon | 25 | 1 | 0 | No | No |
| 17082666 | Arylamide compounds and compositions and uses thereof | October 2020 | October 2023 | Abandon | 36 | 3 | 0 | No | No |
| 17049737 | COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING A VASCULAR DISRUPTING AGENT AND TAXANE COMPOUND | October 2020 | February 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17073920 | METHODS OF TREATING HEPATITIS DELTA VIRUS INFECTION | October 2020 | July 2022 | Allow | 21 | 1 | 0 | No | No |
| 17047570 | METHODS OF TREATING NEUROPATHIC PAIN | October 2020 | August 2023 | Abandon | 34 | 2 | 0 | No | No |
| 17063470 | USE OF METHYLNALTREXONE TO ATTENUATE TUMOR PROGRESSION | October 2020 | September 2022 | Abandon | 24 | 1 | 0 | No | No |
| 17012448 | USE OF THE PHYTOCANNABINOID CANNABIDIVARIN (CBDV) IN THE TREATMENT OF EPILEPSY | September 2020 | February 2024 | Allow | 41 | 2 | 0 | No | No |
| 17008913 | TOPICAL FORMULATIONS OF CHLOROPROCAINE AND METHODS OF USING SAME | September 2020 | November 2023 | Allow | 38 | 3 | 0 | No | No |
| 16998867 | COMPOSITION FOR PREVENTION OR TREATMENT OF NEUROINFLAMMATORY DISEASE, CONTAINING PROTEIN TYROSINE PHOSPHATASE | August 2020 | September 2023 | Abandon | 37 | 3 | 0 | No | No |
| 16991440 | Augmenting Moieties for Anti-Inflammatory Compounds | August 2020 | April 2023 | Allow | 32 | 2 | 1 | No | No |
| 16986492 | METHOD OF TREATING CANCER USING SELECTIVE ESTROGEN RECEPTOR MODULATORS | August 2020 | March 2023 | Abandon | 31 | 2 | 0 | No | No |
| 16985220 | TREATMENT OF LEIGH SYNDROME AND LEIGH-LIKE SYNDROME WITH TOCOTRIENOL QUINONES | August 2020 | August 2021 | Abandon | 13 | 1 | 0 | No | No |
| 16942312 | METHOD FOR PREVENTING OR TREATING ALZHEIMER'S DISEASE | July 2020 | August 2022 | Allow | 25 | 1 | 0 | Yes | No |
| 16963843 | COMPOSITION FOR PREVEINTING OR TREATING DRY EYE SYNDROME CONTAINING ALPHA-HUMULENE AS ACTIVE INGREDIENT | July 2020 | June 2023 | Allow | 35 | 2 | 0 | Yes | No |
| 16931170 | COMBINATION THERAPY FOR CANCER USING BROMODOMAIN AND EXTRA-TERMINAL (BET) PROTEIN INHIBITORS | July 2020 | August 2022 | Abandon | 25 | 1 | 0 | No | No |
| 16961242 | PRODRUGS OF ALOX-15 INHIBITORS AND METHODS OF USING THE SAME | July 2020 | May 2021 | Allow | 10 | 1 | 0 | No | No |
| 16922958 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | July 2020 | May 2022 | Allow | 22 | 1 | 0 | Yes | No |
| 16957774 | PERCUTANEOUS ABSORPTION PREPARATION FOR TREATING DEMENTIA COMPRISING DONEPEZIL | June 2020 | February 2024 | Allow | 44 | 2 | 0 | No | No |
| 16869879 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | May 2020 | January 2024 | Abandon | 45 | 3 | 0 | No | No |
| 16869277 | INJECTABLE IBUPROFEN FORMULATION | May 2020 | September 2023 | Allow | 41 | 4 | 0 | Yes | No |
| 16856624 | SYNERGISTIC COMBINATIONS OF UROLITHINS A AND B FOR IMPROVING COGNITIVE CAPACITY OR COGNITIVE FUNCTION | April 2020 | December 2023 | Abandon | 44 | 3 | 0 | Yes | No |
| 16853885 | THERAPEUTIC AGENT FOR ANXIETY DISORDERS | April 2020 | May 2022 | Abandon | 25 | 1 | 0 | No | No |
| 16833819 | Combination Therapy | March 2020 | August 2022 | Abandon | 28 | 1 | 0 | No | No |
| 16829299 | Substituted 1-Arylalkyl-4-Acylaminopiperidine Compounds and Methods of Producing and Using the Same | March 2020 | May 2022 | Allow | 25 | 2 | 0 | No | No |
| 16644811 | NON-DESTRUCTIVE SAMPLING DEVICE FOR EXTRACTION OF A MARKER | March 2020 | March 2023 | Abandon | 37 | 0 | 1 | No | No |
| 16792930 | NON-VOLATILE ORGANIC COMPOUND PESTICIDE FORMULATIONS | February 2020 | August 2022 | Allow | 30 | 2 | 0 | No | No |
| 16784574 | Morphinan Derivatives for the Treatment of Drug Overdose | February 2020 | September 2021 | Abandon | 19 | 1 | 0 | No | No |
| 16784362 | COMPOSITIONS AND METHODS FOR TREATING EPILEPSY | February 2020 | March 2022 | Allow | 25 | 2 | 0 | Yes | No |
| 16779251 | METHODS FOR THE TREATMENT OF INFECTION | January 2020 | October 2021 | Abandon | 20 | 1 | 0 | No | No |
| 16741100 | NOVEL LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | January 2020 | March 2022 | Allow | 26 | 1 | 0 | Yes | No |
| 16739262 | Morphinan Derivatives with High Oral Bioavailability | January 2020 | January 2022 | Abandon | 24 | 1 | 1 | No | No |
| 16726857 | METHODS OF TREATING MIXED DYSLIPIDEMIA AND HYPERTRIGLYCERIDEMIA | December 2019 | May 2022 | Allow | 28 | 3 | 0 | No | No |
| 16724903 | PHARMACEUTICAL COMPOSITIONS COMPRISING DEXTROMETHORPHAN AND QUINIDINE FOR THE TREATMENT OF DEPRESSION, ANXIETY, AND NEURODEGENERATIVE DISORDERS | December 2019 | June 2021 | Abandon | 18 | 1 | 0 | No | No |
| 16721329 | METHOD OF TREATING CANCER USING SELECTIVE ESTROGEN RECEPTOR MODULATORS | December 2019 | September 2020 | Abandon | 9 | 1 | 0 | No | No |
| 16710091 | PHARMACEUTICAL COMPOSITIONS COMPRISING DEXTROMETHORPHAN AND QUINIDINE FOR THE TREATMENT OF AGITATION IN DEMENTIA | December 2019 | June 2021 | Abandon | 18 | 1 | 0 | No | No |
| 16700157 | MATERIALS AND METHODS FOR DETECTING AND/OR TREATING DUCTAL CARCINOMA IN SITU AND RELATED SYMPTOMS | December 2019 | December 2022 | Abandon | 36 | 0 | 1 | No | No |
| 16667300 | USE OF METHYLNALTREXONE TO ATTENUATE TUMOR PROGRESSION | October 2019 | October 2020 | Abandon | 12 | 1 | 0 | No | No |
| 16596236 | PHARMACEUTICAL COMPOSITIONS COMPRISING A DEXTROMETHORPHAN COMPOUND AND QUINIDINE FOR THE TREATMENT OF AGITATION IN DEMENTIA | October 2019 | May 2023 | Abandon | 43 | 3 | 1 | No | No |
| 16591879 | PHARMACEUTICAL COMPOSITIONS COMPRISING DEXTROMETHORPHAN AND QUINIDINE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | October 2019 | December 2021 | Abandon | 26 | 2 | 0 | No | No |
| 16584667 | COMPOSITIONS AND METHODS FOR TREATING BETA-AMYLOID RELATED DISEASES | September 2019 | October 2021 | Abandon | 24 | 1 | 0 | No | No |
| 16584103 | METHODS AND COMPOSITIONS FOR TREATING PAIN | September 2019 | April 2022 | Allow | 31 | 2 | 0 | Yes | No |
| 16568827 | THERAPEUTIC AGENT FOR ANXIETY DISORDERS | September 2019 | August 2020 | Abandon | 12 | 1 | 0 | No | No |
| 16566744 | ANTICANCER COMBINATION OF CHIDAMIDE AND CELECOXIB SALTS | September 2019 | June 2023 | Allow | 46 | 4 | 1 | Yes | No |
| 16549828 | METHOD OF TREATING CANCER USING SELECTIVE ESTROGEN RECEPTOR MODULATORS | August 2019 | March 2022 | Abandon | 31 | 1 | 1 | No | No |
| 16547478 | NICOTINE FORMULATION FOR ACTIVE MESH NEBULIZER | August 2019 | September 2021 | Abandon | 25 | 2 | 0 | Yes | No |
| 16511774 | ARYL ISONITRILES AS A NEW CLASS OF ANTIMICROBIAL COMPOUNDS | July 2019 | October 2021 | Allow | 27 | 2 | 1 | Yes | Yes |
| 16511053 | ARYL ISONITRILES AS A NEW CLASS OF ANTIMICROBIAL COMPOUNDS | July 2019 | June 2021 | Allow | 23 | 2 | 0 | No | No |
| 16443945 | ARYL ISONITRILES AS A NEW CLASS OF ANTIMICROBIAL COMPOUNDS | June 2019 | June 2021 | Allow | 24 | 2 | 1 | No | No |
| 16419884 | Method for activating AMPK and the use of Adenine | May 2019 | July 2022 | Allow | 38 | 5 | 1 | Yes | No |
| 16463347 | METHODS FOR TREATING OPIOID ADDICTION | May 2019 | May 2023 | Abandon | 47 | 4 | 1 | No | No |
| 16419226 | Therapeutic Combination for the Treatment of Cancer | May 2019 | May 2021 | Abandon | 24 | 2 | 0 | No | Yes |
| 16461716 | ALLOSTERIC ANTAGONISTS OF GPRC6a AND THEIR USE IN MITIGATING PROTEINOPATHIES | May 2019 | December 2021 | Abandon | 31 | 1 | 1 | No | No |
| 16413147 | COMPOUNDS FOR TREATMENT OF TRIPLE NEGATIVE BREAST CANCER AND OVARIAN CANCER | May 2019 | September 2024 | Abandon | 60 | 6 | 1 | No | No |
| 16413222 | COMPOUNDS FOR TREATMENT OF PANCREATIC CANCER | May 2019 | September 2024 | Abandon | 60 | 6 | 0 | No | No |
| 16412205 | USE OF TRPV4 ANTAGONISTS TO AMELIORATE HYDROCEPHALUS AND RELATED MATERIALS AND METHODS | May 2019 | December 2021 | Allow | 31 | 4 | 0 | Yes | Yes |
| 16411861 | HEPATOTOXICITY-FREE PHARMACEUTICAL COMPOSITION CONTAINING ACETAMINOPHEN DRUGS | May 2019 | August 2022 | Allow | 39 | 3 | 1 | Yes | No |
| 16347648 | ORAL COMPOSITION WITH IMMUNOMODULATING EFFECT ON NATURAL KILLER CELLS | May 2019 | June 2021 | Abandon | 25 | 2 | 0 | Yes | No |
| 16403247 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | May 2019 | August 2020 | Allow | 15 | 1 | 0 | No | No |
| 16346563 | THERAPY OF POST-OPERATIVE EMESIS WITH AMISULPRIDE | May 2019 | August 2023 | Abandon | 51 | 4 | 0 | No | Yes |
| 16094183 | USE OF FENOFIBRIC ACID IN THE TREATMENT OF HEPATIC DISEASES | April 2019 | October 2020 | Abandon | 24 | 1 | 0 | No | No |
| 16397200 | METHODS OF TREATING COMPLEX REGIONAL PAIN SYNDROME (CRPS) OR SYMPTOMS COMPRISING ADMINISTRATION OF NERIDRONIC ACID | April 2019 | December 2022 | Abandon | 44 | 4 | 1 | Yes | No |
| 16345995 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | April 2019 | October 2020 | Abandon | 17 | 1 | 0 | No | No |
| 16395689 | SYNERGISTIC COMPOSITION FOR INHIBITING ADVANCED GLYCATION END PRODUCT CROSSLINKING | April 2019 | May 2021 | Abandon | 24 | 1 | 1 | No | No |
| 16345329 | MEMANTINE COMBINATIONS AND USE | April 2019 | May 2021 | Abandon | 24 | 1 | 1 | No | No |
| 16366404 | OSMOTIC PUMP CONTROLLED RELEASE FORMULATIONS | March 2019 | October 2022 | Abandon | 43 | 0 | 1 | No | No |
| 16365148 | METHOD FOR TREATING CONDITIONS ASSOCIATED WITH HYPERPROLIFERATING CELLS COMPRISING COMBINED ADMINISTRATION OF A CANNABINOID RECEPTOR AGONIST AND RADIATION THERAPY | March 2019 | June 2023 | Allow | 51 | 5 | 1 | No | No |
| 16364436 | METHODS OF TREATING BRAIN CANCER USING AGENTS THAT ALTER ACTIVITY OF A METABOLIC PATHWAY | March 2019 | November 2020 | Abandon | 19 | 1 | 1 | No | No |
| 16364431 | COMPOSITIONS AND METHODS FOR INHIBITING DIHYDROOROTATE DEHYDROGENASE | March 2019 | March 2022 | Abandon | 36 | 3 | 1 | Yes | No |
| 16336879 | NICOTINIC ACETYLCHOLINE RECEPTOR AGONIST ATTENUATES ILC2-DEPENDENT AIRWAY HYPERREACTIVITY | March 2019 | July 2022 | Abandon | 40 | 3 | 1 | Yes | No |
| 16336358 | Methods For Treating Ovarian Cancer | March 2019 | January 2023 | Abandon | 46 | 4 | 0 | No | No |
| 16335716 | DRUG-INDUCED EPIGENETIC REMODELING TO PREVENT FIBROSIS | March 2019 | April 2022 | Allow | 37 | 2 | 1 | No | No |
| 16335747 | USE OF HARRINGTONINES IN THE TREATMENT OF BREAST CANCER, IN PARTICULAR TRIPLE-NEGATIVE BREAST CANCER | March 2019 | June 2021 | Abandon | 27 | 1 | 0 | No | No |
| 16335693 | Antiestrogens and/or Aromatase Inhibitors for Use in Treating Obesity and Related Symptoms | March 2019 | May 2021 | Abandon | 26 | 0 | 1 | No | No |
| 16362525 | NOVEL METHODS | March 2019 | June 2021 | Abandon | 27 | 1 | 0 | No | No |
| 16358311 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | March 2019 | May 2023 | Abandon | 50 | 5 | 1 | Yes | No |
| 16351620 | PHARMACEUTICAL COMPOUNDS | March 2019 | October 2020 | Allow | 19 | 2 | 0 | Yes | No |
| 16297590 | Compositions and Methods for Treating Aging and Age-Related Diseases and Symptoms | March 2019 | October 2022 | Abandon | 43 | 5 | 0 | No | No |
| 16290827 | CANCER TREATMENT | March 2019 | May 2021 | Abandon | 26 | 2 | 0 | No | No |
| 16268230 | 2 x 2 x 2 WEEK DOSING REGIMEN FOR TREATING ACTINIC KERATOSIS WITH PHARMACEUTICAL COMPOSITIONS FORMULATED WITH 3.75% IMIQUIMOD | February 2019 | December 2021 | Allow | 34 | 2 | 0 | No | No |
| 16249884 | INJECTABLE IBUPROFEN FORMULATION | January 2019 | September 2020 | Abandon | 20 | 2 | 0 | Yes | No |
| 16239529 | Treatment of Bladder Cancer by Intratumoral Injection of Taxane Particles | January 2019 | July 2020 | Abandon | 19 | 2 | 0 | No | No |
| 16239527 | Treatment of Bladder Cancer by Local Administration of Taxane Particles | January 2019 | October 2021 | Abandon | 33 | 3 | 0 | No | Yes |
| 16233315 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | December 2018 | February 2021 | Allow | 25 | 2 | 0 | No | No |
| 16311776 | THERMOSTABLE FORMULATION OF BIOLOGICALLY ACTIVE SUBSTANCES | December 2018 | January 2022 | Allow | 37 | 2 | 1 | No | No |
| 16227440 | Methods of Treatment of Hypertriglyceridemia | December 2018 | January 2021 | Abandon | 25 | 2 | 0 | No | No |
| 16311969 | ENHANCING DNA REPAIR AND PREVENTING AGING AND ITS CONSEQUENCES IN REPRODUCTIVE AND OTHER CELLS | December 2018 | June 2021 | Abandon | 30 | 2 | 1 | No | No |
| 16311748 | SYNERGISTIC EFFECTS, AUGMENTING ANTIMICROBAL EFFECTS OF LIPIDS | December 2018 | January 2023 | Abandon | 49 | 4 | 1 | No | No |
| 16311533 | SMALL MOLECULE INHIBITORS OF ALDH AND USES THEREOF | December 2018 | November 2023 | Allow | 59 | 6 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MCMILLIAN, KARA RENITA.
With a 20.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 12.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner MCMILLIAN, KARA RENITA works in Art Unit 1627 and has examined 800 patent applications in our dataset. With an allowance rate of 24.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 35 months.
Examiner MCMILLIAN, KARA RENITA's allowance rate of 24.4% places them in the 3% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by MCMILLIAN, KARA RENITA receive 2.33 office actions before reaching final disposition. This places the examiner in the 62% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by MCMILLIAN, KARA RENITA is 35 months. This places the examiner in the 38% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +40.0% benefit to allowance rate for applications examined by MCMILLIAN, KARA RENITA. This interview benefit is in the 86% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 10.7% of applications are subsequently allowed. This success rate is in the 7% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 20.4% of cases where such amendments are filed. This entry rate is in the 27% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 50.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 43% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 50.8% of appeals filed. This is in the 22% percentile among all examiners. Of these withdrawals, 58.1% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 63.9% are granted (fully or in part). This grant rate is in the 67% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.4% of allowed cases (in the 56% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.